Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGON 
CG Oncology, Inc. Common stock (CGON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/01/2025: CGON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $70.77
1 Year Target Price $70.77
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.54% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.49B USD | Price to earnings Ratio - | 1Y Target Price 70.77 |
Price to earnings Ratio - | 1Y Target Price 70.77 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 14.80 - 45.94 | Updated Date 12/2/2025 |
52 Weeks Range 14.80 - 45.94 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.05 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.5467 | Actual -0.57 |
Profitability
Profit Margin - | Operating Margin (TTM) -3068.97% |
Management Effectiveness
Return on Assets (TTM) -17.56% | Return on Equity (TTM) -24.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2944049466 | Price to Sales(TTM) 1604.79 |
Enterprise Value 2944049466 | Price to Sales(TTM) 1604.79 | ||
Enterprise Value to Revenue 1354.21 | Enterprise Value to EBITDA - | Shares Outstanding 80666179 | Shares Floating 65435598 |
Shares Outstanding 80666179 | Shares Floating 65435598 | ||
Percent Insiders 2.98 | Percent Institutions 108.88 |
Upturn AI SWOT
CG Oncology, Inc. Common stock
Company Overview
History and Background
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing oncolytic immunotherapies for cancer. Founded in 2010, the company is dedicated to developing a potential bladder cancer treatment.
Core Business Areas
- Oncolytic Immunotherapy Development: Focuses on developing and commercializing oncolytic viruses designed to selectively kill cancer cells and stimulate an immune response.
Leadership and Structure
Arthur Kuan is the CEO. The organizational structure includes departments for research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Cretostimogene grenadenorepvec (creto): An oncolytic immunotherapy being developed for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy is currently in Phase 3 clinical trials. Market share is currently 0% as it is not approved. Competitors include FerGene (nadofaragene firadenovec), Merck (Keytruda for BCG-unresponsive NMIBC).
Market Dynamics
Industry Overview
The oncolytic virus therapy market is growing, driven by the need for novel cancer treatments and advances in biotechnology. The bladder cancer treatment market is competitive.
Positioning
CG Oncology aims to be a leader in the oncolytic immunotherapy field, focusing on bladder cancer with cretostimogene grenadenorepvec (creto).
Total Addressable Market (TAM)
The global bladder cancer therapeutics market is estimated to reach billions of dollars. CG Oncology is focused on capturing a significant share of the NMIBC market.
Upturn SWOT Analysis
Strengths
- Promising Phase 3 clinical trial results for creto
- Strong scientific team
- Focus on a specific, unmet medical need
Weaknesses
- Reliance on a single product candidate
- Limited commercial infrastructure
- Dependent on clinical trial success
Opportunities
- Potential for regulatory approval and market launch of creto
- Expansion to other cancer indications
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- FGEN
Competitive Landscape
CG Oncology faces competition from existing therapies and other companies developing novel bladder cancer treatments. Their success will depend on demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the progression of clinical trials and regulatory milestones.
Future Projections: Future growth depends on the successful commercialization of creto and potential expansion into other indications.
Recent Initiatives: Focus is on completing the Phase 3 trial and preparing for potential regulatory submissions.
Summary
CG Oncology is a development-stage company with a promising oncolytic immunotherapy candidate for bladder cancer. The company's success hinges on positive clinical trial results and regulatory approval. Risks include clinical trial failures and competition from other therapies. The company's focus and strategic partnerships may help improve its success and expansion in the market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual financial circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2024-01-25 | Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://cgoncology.com |
Full time employees 113 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.